In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales

BACKGROUND: Sulbactam-durlobactam is a potent combination active against Acinetobacter baumannii; however, it lacks activity against other nosocomial pathogens. Cefepime is a common first-line therapy for hospital/ventilator-associated pneumonia caused by Gram-negative pathogens including Pseudomona...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouad, Aliaa, Nicolau, David P, Gill, Christian M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689914/
https://www.ncbi.nlm.nih.gov/pubmed/37839896
http://dx.doi.org/10.1093/jac/dkad244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689914/
https://www.ncbi.nlm.nih.gov/pubmed/37839896
http://dx.doi.org/10.1093/jac/dkad244

Ejemplares similares